365 related articles for article (PubMed ID: 11370251)
1. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S59-76. PubMed ID: 11370251
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis in Sudan. Visceral leishmaniasis.
Zijlstra EE; el-Hassan AM
Trans R Soc Trop Med Hyg; 2001 Apr; 95 Suppl 1():S27-58. PubMed ID: 11370250
[TBL] [Abstract][Full Text] [Related]
3. Post-kala-azar dermal leishmaniasis.
Zijlstra EE; Musa AM; Khalil EA; el-Hassan IM; el-Hassan AM
Lancet Infect Dis; 2003 Feb; 3(2):87-98. PubMed ID: 12560194
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
7. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
8. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
9. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients.
Salih MA; Fakiola M; Abdelraheem MH; Younis BM; Musa AM; ElHassan AM; Blackwell JM; Ibrahim ME; Mohamed HS
BMC Infect Dis; 2014 Dec; 14():662. PubMed ID: 25466928
[TBL] [Abstract][Full Text] [Related]
10. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
12. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
13. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
Saha S; Mazumdar T; Anam K; Ravindran R; Bairagi B; Saha B; Goswami R; Pramanik N; Guha SK; Kar S; Banerjee D; Ali N
J Clin Microbiol; 2005 Mar; 43(3):1269-77. PubMed ID: 15750095
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
15. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
16. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
17. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
18. Use of PCR for diagnosis of post-kala-azar dermal leishmaniasis.
Osman OF; Oskam L; Kroon NC; Schoone GJ; Khalil ET; El-Hassan AM; Zijlstra EE; Kager PA
J Clin Microbiol; 1998 Jun; 36(6):1621-4. PubMed ID: 9620389
[TBL] [Abstract][Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
20. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]